CT HALF and CZECRIN part of the Olomouc Hematology Days

On Thursday, May 26, 2022, the first day of Congress XXXIV. Olomouc Hematology Days (https://www.olhemdny.cz/), a meeting of the CELL and the Leukemia Section took place, which included an investigative meeting of the HALF clinical trial. The meeting was attended not only by doctors, but also by nurses and coordinators, and 8 lectures focused on current topics, such as the current course of the study, patient recruitment, sample logistics or information on the awarded AZV grant and its processing. The lecture by VI CZECRIN was also included in the program, which acquainted the participants with the current state of filling in data into the database and general conclusions from the current monitoring of the centers.

The HALF study aims to evaluate the efficacy and safety of tyrosine kinase inhibitors after a previous two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission. The sponsor of the multicenter clinical trial is Masaryk University and so far 7 centers have been initiated, the last center is undergoing final preparations for its initiation. The recruitment of subjects to the study is extended until 31 December 2022 and 159 patients are currently enrolled.